Skip to main content

Research Repository

Advanced Search

Anticancer Ruthenium(η6-p-cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives

Aman, Farhana; Hanif, Muhammad; Siddiqui, Waseeq Ahmad; Ashraf, Adnan; Filak, Lukas K.; Reynisson, Jóhannes; Söhnel, Tilo; Jamieson, Stephen M. F.; Hartinger, Christian G.

Authors

Farhana Aman

Muhammad Hanif

Waseeq Ahmad Siddiqui

Adnan Ashraf

Lukas K. Filak

Tilo Söhnel

Stephen M. F. Jamieson

Christian G. Hartinger



Abstract

Oxicams are a versatile family of heterocyclic compounds, and the two representatives meloxicam and piroxicam are widely used drugs for the treatment of a variety of inflammatory and rheumatic diseases in humans. As cancer-associated inflammation is known to occur in carcinogenesis, we aimed to combine compounds carrying bioactive oxicam moieties with ruthenium(arene) fragments, known for anticancer activity. RuII(arene) complexes with methyl ester derivatives of the oxicam scaffold were prepared and characterized by standard methods and crystallographically. The organoruthenium compounds formed from RuII(η6-p-cymene) chlorido moieties and oxicam-based ligands were subjected to bioanalytical investigations to establish their physicochemical properties with regard to stability in DMSO and water as well as reactivity toward the amino acids l-histidine (His), l-methionine (Met), and l-cysteine (Cys) and the DNA model compound guanosine 5′-monophosphate (5′-GMP). The compounds hydrolyzed rapidly in water to give the respective aqua complexes, formed amino acid complexes with Met and His, but decompose with Cys, while interaction with 5′-GMP was through its phosphate residue. The anticancer activity of the complexes against the colon carcinoma HCT116 and breast cancer MDA MB 231 cancer cell lines was established using an in vitro assay. The cytotoxicity was found strongly dependent on the lipophilicity of the compound, as was shown through correlation with log kw and clog P values of the ligands. The most lipophilic compound [chlorido(methyl 4-oxido-2-benzyl-2H-1,2-benzothiazine-3-carboxylate-1,1-dioxide)(η6-p-cymene)ruthenium(II)] was the most active in the cell assays, with an IC50 of 80 μM in HCT116 cells.

Citation

Aman, F., Hanif, M., Siddiqui, W. A., Ashraf, A., Filak, L. K., Reynisson, J., …Hartinger, C. G. (2014). Anticancer Ruthenium(η6-p-cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives. Organometallics, 33(19), 5546-5553. https://doi.org/10.1021/om500825h

Journal Article Type Article
Online Publication Date Sep 26, 2014
Publication Date Oct 13, 2014
Deposit Date Jun 7, 2023
Journal Organometallics
Print ISSN 0276-7333
Electronic ISSN 1520-6041
Publisher American Chemical Society
Peer Reviewed Peer Reviewed
Volume 33
Issue 19
Pages 5546-5553
DOI https://doi.org/10.1021/om500825h
Keywords Inorganic Chemistry; Organic Chemistry; Physical and Theoretical Chemistry